Abzena Announces Successful Technical Transfer of Synaffix GlycoConnect? Antibody Drug Conjugate (ADC) Technology to Enable Use in Client Projects

SAN DIEGO–(BUSINESS WIRE)–Abzena, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect? (antibody conjugation) and HydraSpace? (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to Abzena?s leadership in process development and GMP manufacturing of ADC linkers and payloads. Abzena can now rapidly ramp up ADC projects using Syn